Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on NGM Biopharmaceuticals (NASDAQ:NGM) Inc on Thursday, setting a price target of $43, which is approximately 47.92% above the present share price of $29.07.
Archila expects NGM Biopharmaceuticals Inc to post earnings per share (EPS) of -$0.40 for the second quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in NGM Biopharmaceuticals, with an average price target of $43.6.
The analysts price targets range from a high of $52 to a low of $39.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $19.77 million and a net profit of -$27.67 million. The company's market cap is $2.23 billion.
According to TipRanks.com, Stifel Nicolaus analyst Derek Archila is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 8.5% and a 45.91% success rate.
NGM Biopharmaceuticals, Inc. engages in the discovery and development of therapeutics for major diseases with an initial focus on cardio-metabolic and liver diseases. Its portfolio if composed of product candidates which focuses on non-alcoholic steatohepatitis, type 2 diabetes, obesity, oncology and age-related macular degeneration. The company was founded by Jin-Long Chen in 2008 and is headquartered in South San Francisco, CA.